These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 24158772

  • 1. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.
    Cancer; 2008 Apr 01; 112(7):1555-61. PubMed ID: 18286536
    [Abstract] [Full Text] [Related]

  • 3. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Perrino M, Lorenzi E, Ceresoli GL, De Vincenzo F, Simonelli M, Gianoncelli L, De Sanctis R, Giordano L, Santoro A.
    Lung Cancer; 2014 Jun 01; 84(3):265-70. PubMed ID: 24321581
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 01; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 5. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A.
    Lung Cancer; 2011 Sep 01; 73(3):351-5. PubMed ID: 21296448
    [Abstract] [Full Text] [Related]

  • 6. Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
    Agatsuma T, Koizumi T, Yasuo M, Urushihata K, Tsushima K, Yamamoto H, Hanaoka M, Fukushima M, Honda T, Kubo K.
    Jpn J Clin Oncol; 2010 Dec 01; 40(12):1180-3. PubMed ID: 20603247
    [Abstract] [Full Text] [Related]

  • 7. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
    Zauderer MG, Kass SL, Woo K, Sima CS, Ginsberg MS, Krug LM.
    Lung Cancer; 2014 Jun 01; 84(3):271-4. PubMed ID: 24690410
    [Abstract] [Full Text] [Related]

  • 8. Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
    Ceresoli GL, Zucali PA.
    Cancer Treat Rev; 2015 Dec 01; 41(10):853-8. PubMed ID: 26526504
    [Abstract] [Full Text] [Related]

  • 9. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.
    J Clin Oncol; 2008 Jul 20; 26(21):3567-72. PubMed ID: 18640937
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov 20; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 11. Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
    Mutlu H, Gündüz S, Karaca H, Büyükçelik A, Cihan YB, Erden A, Akca Z, Coşkun HS.
    Med Oncol; 2014 Aug 20; 31(8):74. PubMed ID: 24958517
    [Abstract] [Full Text] [Related]

  • 12. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
    Jpn J Clin Oncol; 2010 Nov 20; 40(11):1031-6. PubMed ID: 20534685
    [Abstract] [Full Text] [Related]

  • 13. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
    de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, Roberts H, Tsao MS, Leighl N, Keshavjee S, Johnston MR.
    J Clin Oncol; 2009 Mar 20; 27(9):1413-8. PubMed ID: 19224855
    [Abstract] [Full Text] [Related]

  • 14. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.
    Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.
    Clin Cancer Res; 2014 Dec 01; 20(23):5927-36. PubMed ID: 25231400
    [Abstract] [Full Text] [Related]

  • 15. An unusually large pleural mesothelioma with an outstanding clinical response and long lasting survival: a case report and literature review.
    Zilembo N, Vitali M, Pietrantonio F, Platania M, Del Vecchio M, Bajetta E.
    Tumori; 2010 Dec 01; 96(6):1031-4. PubMed ID: 21388071
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.
    Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba I.
    Clin Lung Cancer; 2014 May 01; 15(3):197-201. PubMed ID: 24492162
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

  • 18. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.
    J Clin Oncol; 2008 Mar 20; 26(9):1465-71. PubMed ID: 18349397
    [Abstract] [Full Text] [Related]

  • 19. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T.
    Oncology; 2021 Mar 20; 99(3):161-168. PubMed ID: 33053560
    [Abstract] [Full Text] [Related]

  • 20. The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
    Wahba NI, Khorshid O, Abo Elkasem F, Bahnassy A, Gaafer R.
    Asian Pac J Cancer Prev; 2023 Jan 01; 24(1):195-205. PubMed ID: 36708568
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.